Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial
Abstract In oncology, the conventional reliance on the maximum tolerated dose (MTD) strategy for chemotherapy may not optimize treatment outcomes for individual patients. CURATE.AI is an AI-derived platform that utilizes a patient’s own, small dataset to dynamically personalize only their own dose r...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Portfolio
2025-02-01
|
| Seri Bilgileri: | npj Precision Oncology |
| Online Erişim: | https://doi.org/10.1038/s41698-025-00835-7 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|